Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

Publisher： Karger

E-ISSN： 1424-0556|1|2|103-109

ISSN： 1422-9528

Source： Heart Drug, Vol.1, Iss.2, 2004-11, pp. : 103-109

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

By Manoharan G.   Maynard S.J.   Adgey A.J.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 555-566

Informa Healthcare

Access to resources Recommend Favorite

Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors: In the Management of Acute Coronary Syndromes

By Bosanquet N.  

PharmacoEconomics, Vol. 21, Iss. 16, 2003-01 ,pp. : 1135-1152

Adis International

Access to resources Recommend Favorite

Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

By Westerhout Cynthia M   Boersma Eric  

Expert Opinion on Drug Safety, Vol. 2, Iss. 1, 2003-01 ,pp. : 49-58

Informa Healthcare

Access to resources Recommend Favorite

Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes

By Salam Amar M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1567-1570

Informa Healthcare

Access to resources Recommend Favorite

Guidance on the use of glycoprotein (GP) IIb/IIIa antagonists in the treatment of acute coronary syndromes

By  

Inpharma, Vol. 1, Iss. 1357, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite